Together these findings indicate that Vandetanib and Nintedanib use different mechanisms downstream of PI3K/AKT to stop MTC growth, although the two TKIs show several mechanistic similarities. The gene discussed is AKT1; the disease is medullary thyroid gland carcinoma.